Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06475729 · ClinicalTrials.gov registry record · Phase 1
A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 498
- Enrollment target
NCT06475729: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT06475729 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 498 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (730% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06475729, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 498 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via autoinjector, an injection under the skin, compared to mirikizumab (reference) solution given via autoinjector. Screening is required within 35 days prior to enrollment. For each participant, the total duration for of the clinical trial will be about 15 weeks, including screening.
Primary Outcome
Cmax of Mirikizumab is reported.
Interventions
- DRUG Citrate-Free Mirikizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 498 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2024-12-27 |
| Phase | Phase 1 |
What the finished NCT06475729 record still lists
NCT06475729 is an interventional study that assigns participants to a tested intervention. The registered 498 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (730% higher).
The record links to 0 conditions, and to 1 intervention - of which Citrate-Free Mirikizumab is the first listed.
NCT06475729 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06475729 about?
NCT06475729 is a clinical study titled "A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants". The purpose of this study is to evaluate the amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via autoinjector, an injection under the skin, compared to mirikizumab (reference) solution given via autoinjector. Screening is requ...
What is the current status of trial NCT06475729?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 498 participants. The study started on 2024-06-24. Estimated completion is 2024-12-27.
What interventions are being tested in trial NCT06475729?
The interventions under investigation include: Citrate-Free Mirikizumab (DRUG).
Who is sponsoring clinical trial NCT06475729?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06475729's enrollment target sits among peer trials
498 47th of 2000 higher than 1,954 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04137900 · 499 participants · Phase 1
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
- NCT06733480 · 499 participants · NA
Innovating Physical Therapy: A Pilot Study on Band Connect's Impact on Compliance, Satisfaction, and Revenue
- NCT03175224 · 497 participants · Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- NCT05301816 · 497 participants · NA
PDN Post Market, Multicenter, Prospective, Global Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI